8-K: BioAffinity Reports Q2 2025: CyPath Lung Revenue Soars

BioAffinity Technologies reported a 62% year-over-year increase in CyPath Lung testing revenue for the first half of 2025, despite an overall decrease in quarterly revenue due to strategic shifts.

Summary

• Total revenue for the second quarter of 2025 was $1.3 million, a decrease from $2.4 million in Q2 2024, primarily due to the strategic discontinuation of unprofitable pathology services.
• CyPath Lung testing revenue for the six months ended June 30, 2025, increased 62% year-over-year to $323,000, driven by growing physician adoption.
• Operating expenses for Q2 2025 decreased 16% to $3.8 million from $4.5 million in Q2 2024, attributed to cost-saving initiatives and reduced research and development expenses.
• Net loss for Q2 2025 increased to $4.1 million, or $0.17 per share, compared to a net loss of $2.1 million, or $0.19 per share, in Q2 2024, largely due to $1.5 million in non-cash warrant remeasurement and offering costs.
• Cash and cash equivalents stood at $0.8 million as of June 30, 2025, down from $1.1 million at December 31, 2024.
• The company completed a $3.25 million public offering in May 2025 to provide working capital.
• Dr. Gordon Downie, MD, PhD, was appointed as Chief Medical Officer, bringing over 30 years of clinical leadership.
• New patent grants were secured in the U.S., China, Canada, and Australia, expanding the global intellectual property portfolio for diagnostics and therapeutics.
• The list price of CyPath Lung was increased to $2,900 to align with private payer reimbursement strategies.
• A partnership with Cardinal Health OptiFreight Logistics was established to enhance national sample delivery capabilities.

Sentiment

Score: 6

Explanation: While overall revenue and net loss worsened due to strategic shifts and non-cash expenses, the core diagnostic product, CyPath Lung, showed strong growth (62% YOY revenue increase, record sales in June/July). Strategic moves like the price increase, logistics partnership, new CMO, and patent grants are positive for future growth and market positioning. The capital raise also strengthened the financial foundation. The negative financial headline numbers are largely explained by a strategic pivot and non-cash items, rather than a fundamental failure of the core product.

Positives

• CyPath Lung testing revenue increased 62% year-over-year for the six-month period ended June 30, 2025, reaching $323,000.
• CyPath Lung tests completed in July represented a 72% increase over the previous monthly average for the first six months of 2025, including back-to-back record monthly sales in June and July.
• Real-world case studies demonstrated the diagnostic utility of CyPath Lung, successfully detecting Stage 1A lung cancers that previous tests and imaging had missed.
• The list price of CyPath Lung was increased to $2,900, aligning with private payer reimbursement strategies and enhancing per-test profitability.
• Expanded logistics capabilities through a partnership with Cardinal Health OptiFreight Logistics, improving sample tracking, cost efficiency, and national delivery reliability.
• Completed a $3.25 million public offering in May 2025, providing essential working capital.
• Appointed Dr. Gordon Downie, MD, PhD, as Chief Medical Officer, adding over 30 years of clinical leadership in pulmonology and interventional lung care.
• Secured patent grants in the U.S., China, Canada, and Australia, expanding the global intellectual property portfolio for both diagnostics and therapeutics, including a new U.S. patent for a broad-spectrum cancer therapy.
• Presented novel siRNA-based cancer therapy research at the 2025 RNA Therapeutics Conference, showcasing potential for selective cancer cell killing.
• Operating expenses decreased 16% year-over-year in Q2 2025 due to cost-saving initiatives and reduced R&D.

Negatives

• Total revenue for the second quarter of 2025 decreased to $1.3 million from $2.4 million in Q2 2024, primarily due to the strategic decision to discontinue unprofitable pathology services.
• Net loss for Q2 2025 increased to $4.1 million, or $0.17 per share, compared with a net loss of $2.1 million, or $0.19 per share, for Q2 2024.
• The increased net loss was primarily driven by $1.5 million in non-cash expenses related to warrant remeasurement and offering costs associated with the May 2025 public offering.
• Cash and cash equivalents as of June 30, 2025, were $0.8 million, a decrease from $1.1 million as of December 31, 2024, despite the capital raise.

Risks

• Actual results may differ materially from current expectations due to various risks and uncertainties that are difficult to predict.
• Inability to successfully implement strategic actions to reduce costs while effectively expanding sales focus on high-margin diagnostics like CyPath Lung.
• Failure of international patents to expand CyPath Lung's global commercialization potential as anticipated.
• Inability of targeted actions to accelerate the commercial growth of CyPath Lung.
• Patient case studies may not continue to underscore the diagnostic power of CyPath Lung in real-world settings as expected.
• Challenges in expanding access to CyPath Lung for patients at risk of lung cancer.
• Difficulties in advancing new diagnostics for diseases like COPD and asthma.
• Other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC.

Future Outlook

The company remains focused on expanding access to CyPath Lung, delivering operational efficiency, and advancing the next generation of diagnostics for diseases like COPD and asthma, as well as new therapeutics. They anticipate continued acceleration of CyPath Lung commercialization and global expansion through international patents.

Management Comments

• Our second quarter results reflect the continued acceleration of our CyPath Lung commercialization strategy, with testing revenue up 62% for the first half of the year.
• This growth is driven by increasing clinical adoption of our noninvasive lung cancer diagnostic and supported by physician-authored case studies showing that CyPath Lung has identified early-stage cancers that other tests missed.
• The success of our pilot marketing program in Texas... has demonstrated that our approach to the medical community is sound and effective.
• We are prepared to meet increased demand as we implement our strategy to enter additional key markets, including our expansion in the Mid-Atlantic region and the Veterans Administration healthcare system.
• During the quarter, we took important steps to strengthen our financial foundation, including a successful $3.25 million public offering and a strategic price adjustment for CyPath Lung to better reflect its value and align with reimbursement from private payers.
• Our intellectual property portfolio continues to grow with newly granted patents in the U.S., China, Canada, and Australia—strengthening both our diagnostic and therapeutic platforms on a global scale.
• Every test we deliver is a step toward earlier cancer detection, better patient care, and stronger value for our shareholders.

Industry Context

BioAffinity Technologies operates in the rapidly evolving biotechnology and medical diagnostics sector, specifically targeting early-stage lung cancer detection and broad-spectrum cancer treatments. The focus on non-invasive diagnostics like CyPath Lung aligns with a broader industry trend towards less invasive, more accessible, and earlier detection methods. The expansion into therapeutic platforms, particularly siRNA-based approaches, positions the company in a competitive and high-growth area of oncology research, seeking to develop targeted therapies with fewer side effects. The strategic shift away from unprofitable pathology services towards high-margin diagnostics reflects a common industry move to optimize portfolios and focus on core competencies with higher growth potential.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or global benchmarks.
• The reported 62% year-over-year growth in CyPath Lung testing revenue for the first half of 2025 indicates strong commercial traction within its niche, which is a positive sign for a novel diagnostic product.
• The increase in list price to $2,900 for CyPath Lung suggests a positioning for premium value, consistent with novel diagnostic tests demonstrating high clinical utility for early cancer detection.
• The company's expansion of its intellectual property portfolio and research into siRNA-based therapies are consistent with innovation-driven strategies seen across the biotech industry, aiming for differentiation and long-term market advantage.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value through accelerated CyPath Lung commercialization, expanded intellectual property, and strategic cost management, but diluted by the public offering and impacted by increased net loss (though explained by non-cash items and strategic pivot).
• Patients: Improved access to early-stage lung cancer detection through CyPath Lung, potentially leading to better outcomes.
• Employees: Strategic shifts and integration of PPLS led to staffing adjustments, implying some impact on personnel.
• Customers (Physicians/Healthcare Systems): Enhanced diagnostic utility and improved logistics for CyPath Lung, potentially leading to wider adoption.
• Creditors: The capital raise and focus on profitability could improve the company's financial stability over the long term.

Next Steps

• Implement strategy to enter additional key markets, including the Mid-Atlantic region and the Veterans Administration healthcare system.
• Advance toward pivotal trials for CyPath Lung.
• Expand access to CyPath Lung.
• Deliver operational efficiency.
• Advance the next generation of diagnostics and therapeutics.

Key Dates

Recommendation

While the overall financial results for Q2 2025 show a significant revenue decrease and increased net loss, these are largely attributable to a strategic decision to discontinue unprofitable pathology services and non-cash expenses related to a recent public offering. The core business, CyPath Lung, demonstrates strong growth with a 62% year-over-year increase in testing revenue for the first half of 2025 and record monthly sales. Strategic initiatives like the price increase, logistics partnership, new Chief Medical Officer appointment, and expanding patent portfolio are positive indicators for future commercialization and long-term value. However, the company is still in a growth phase with increasing net losses and declining cash, necessitating a 'hold' recommendation as investors await further evidence of sustained profitability and successful market expansion for CyPath Lung to offset the overall financial headwinds.

Keywords

bioAffinity Technologies, BIAF, CyPath Lung, lung cancer detection, noninvasive diagnostic, biotechnology, early-stage cancer, pulmonology, cancer therapy, siRNA, patents, medical diagnostics, biopharma, Nasdaq